News

CPDC Announces Appointment of Justyna Kelly as Permanent CEO

Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of

ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund

VANCOUVER, Canada and NEW YORK, United States, May 20, 2020 – ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by New York based Deerfield Management Company with

CPDC’s Radiopharmaceutical Manufacturing Facility Receives Clearance from FDA

Hamilton, Ontario, Canada – January 9, 2020 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC’s site in Hamilton, Ontario, is cleared to ship products to the U.S.  Justyna Kelly, interim

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario, December 3, 2019 – Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing as of today that the Company’s Board of Directors has appointed Justyna Kelly as Interim Chief Executive Officer effective immediately. Dr.  Joe McCann will stay on as an Advisor

Study gives Ontario men access to advanced prostate cancer imaging

LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA

Chuck Conroy Appointed CEO of ARTMS

VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 years of experience

ARTMS Products Received $1.5 Million of Funding from the Federal Government

VANCOUVER, British Columbia–ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity program. The federal

CPDC Celebrates Successful FDA Inspection!

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event

CPDC joins forces with the Canadian Nuclear Isotope Council

Hamilton, Ontario, February 19, 2019 – As Canada strives to maintain a leadership position in science and technology, the Centre for Probe Development and Commercialization (CPDC), located at McMaster University, has partnered with the Canadian Nuclear Isotope Council (CNIC) to ensure Canada remains at the forefront of medical isotope R&D and production, and to advocate

Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as

Centre for Probe Development & Commercialization (CPDC) Appoints New CEO and President

Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will

CPDC and McMaster Nuclear Reactor Sign Research Agreement for Production of High Value Medical Isotopes

HAMILTON, Ontario, September 13, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the

ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb’s CD8 Immuno PET Tracer

Shipping Pig

LOS ANGELES, August 29, 2018 – ImaginAb Inc, an immuno-oncology imaging company, and Centre for Probe Development and Commercialization (CPDC), a Canadian centre of excellence specializing in radiopharmaceutical development and cGMP manufacturing, today announced that they have entered into a development and manufacturing agreement for the supply of ImaginAb’s clinical-phase Positron Emission Tomography (PET) imaging

Canada’s science minister announces $10.5 million federal boost for McMaster research commercialization

Hamilton, Ontario – July 30, 2018 – McMaster’s Centre for Probe Development and Commercialization, which converts research on medical isotopes into new diagnostic tests and cancer treatments, has received a significant boost in the form of $10.5 million in federal funding. Canada’s Minister of Science and Sport Kirsty Duncan visited the university’s commercialization hub at

CPDC’s collaborative partner ARTMS Products Inc. raises $3 Million USD to advance a safe alternative way to locally produce medical isotopes and avoid future supply disruptions

Vancouver, British Columbia. – December 18, 2017 – Today, CPDC’s collaborative partner ARTMS Products Inc., the leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotope, announced it has raised $3 million USD. The investment comes from Quark Venture Inc. and GF Securities, through their Global Health

Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics

Shipping Pig

HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD. New investors in the second

CPDC Launches Fusion Pharmaceuticals with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation – JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT (Fight Against

CPDC In-Licenses Enabling Technology to Advance Effectiveness of Immunotherapy

The Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, announces that it has licensed the Centyrin® platform from Janssen Biotech, Inc. for exclusive use in combination with its radiopharmaceutical expertise to create novel nuclear imaging probes against immunotherapy drug targets. Immunotherapy has become one of the most active areas in

Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production

MADISON, Wis., Nov. 28, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced it has selected Hamilton, Ontario-based Centre for Probe Development and Commercialization (CPDC), a well-respected GMP manufacturing organization specializing in radiopharmaceuticals, as a supplier of the company’s lead phospholipid drug conjugate (PDC), CLR 131.

Two top research organizations join to speed cancer research with molecular probes

Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, will work together to create novel molecular probes for non-invasive imaging in cancer research, drug development and patient care. The two leading organizations will form an International Probe Development Consortium (IPDC) to enable and support their collaboration.

FACIT Announces Investment

FACIT and Fusion Pharmaceuticals (“Fusion”) announced an investment to support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.

NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99

NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99 (Vancouver, BC) – For their outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, interdisciplinary research team CycloMed99 will be receiving a prestigious national award at a ceremony in Ottawa today. The Honourable David Johnston, Governor General of Canada,

CPDC Cancer Imaging Research Programs Receive Renewed Funding of $2.9 Million from OICR

Investment acknowledges groundbreaking progress and provides CPDC with additional resources to continue work to bring new radiopharmaceuticals for personalized cancer diagnosis and treatment to clinical use in Ontario. HAMILTON ON and LONDON ON: APRIL 23, 2012 – Cancer research in Ontario, aimed at developing the next generation of radiopharmaceuticals, received a financial boost today. The

Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials

Canadian centre of excellence partners with US-based Molecular Insight Pharmaceuticals to manufacture a new radiopharmaceutical for clinical trials that will evaluate the potential to deliver targeted radiotherapy directly to metastatic prostate cancer. HAMILTON, ON, and CAMBRIDGE, MA: JANUARY 30, 2012— A new targeted radiopharmaceutical, designed to deliver a therapeutic dose of radiation directly to metastatic

McMaster, CPDC open new $22-million nuclear research facility

Hamilton, Ont. August 24, 2011—McMaster University officially unveiled today its newly expanded Nuclear Research Building, a new cyclotron facility and improvements to the McMaster Nuclear Reactor (MNR) Building: facilities which are now available for the world’s leading nuclear scientists and engineers. Nuclear sciences and engineering received $22-million from the federal and provincial governments in 2009

Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases

CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes. TORONTO, ON (June 22, 2011)—CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development

CPDC Joins National Project to Develop Alternative Sources of Medical Isotopes

Non-reactor-based production of medical isotopes could provide Canadians with back-up or supplementary supplies and ease disruptions to patient scans. HAMILTON, ON: JANUARY 24, 2011 – The Centre for Probe Development and Commercialization (CPDC) joined the Government of Canada today to announce a national project to develop alternative sources of medical isotopes that could help to

Scientific Director among Top 40 Under 40

HAMILTON: JUNE 7, 2010 – A McMaster University professor, working on the next generation of molecular imaging probes for the early detection of disease, has been named one of Canada’s Top 40 Under 40. John Valliant, associate professor in the departments of Chemistry and Medical Physics, and CEO and scientific director of the Centre for

Scientific Director delivers SNM opening plenary lecture

HAMILTON: JUNE 14, 2009 –Challenging times are shaping the future of molecular imaging probe development and nuclear medicine, according to the CPDC’s John Valliant. Valliant, PhD, scientific director and CEO at the CPDC, spoke at the Society of Nuclear Medicine’s Annual Meeting in Toronto on June 14, 2009, where he urged scientists to be innovative

Examining the Future of Molecular Imaging

HAMILTON: FEBRUARY 9, 2009 – The future of molecular imaging and its impact on patient care highlighted the CPDC’s inaugural probe development workshop on January 30. More than 120 participants, spanning multiple sectors – academia, health care, not-for-profit, federal/provincial government and industry – gathered at the University Club on McMaster University’s campus in Hamilton, Ontario.

For more information contact us at: